ALTHX Stock Overview
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Theranexus Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.06 |
| 52 Week High | €3.18 |
| 52 Week Low | €0.63 |
| Beta | 2.35 |
| 1 Month Change | 0.67% |
| 3 Month Change | 1.64% |
| 1 Year Change | -27.14% |
| 3 Year Change | -92.51% |
| 5 Year Change | -83.41% |
| Change since IPO | -93.53% |
Recent News & Updates
Shareholder Returns
| ALTHX | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 0.5% | -1.6% | -0.03% |
| 1Y | -27.1% | -14.5% | 1.8% |
Return vs Industry: ALTHX underperformed the French Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: ALTHX underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| ALTHX volatility | |
|---|---|
| ALTHX Average Weekly Movement | 13.2% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALTHX's share price has been volatile over the past 3 months.
Volatility Over Time: ALTHX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | Mathieu Charvériat | www.theranexus.com |
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus Société Anonyme Fundamentals Summary
| ALTHX fundamental statistics | |
|---|---|
| Market cap | €8.19m |
| Earnings (TTM) | -€6.92m |
| Revenue (TTM) | €246.58k |
33.2x
P/S Ratio-1.2x
P/E RatioIs ALTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTHX income statement (TTM) | |
|---|---|
| Revenue | €246.58k |
| Cost of Revenue | €4.31m |
| Gross Profit | -€4.06m |
| Other Expenses | €2.86m |
| Earnings | -€6.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.89 |
| Gross Margin | -1,648.34% |
| Net Profit Margin | -2,808.04% |
| Debt/Equity Ratio | 147.3% |
How did ALTHX perform over the long term?
See historical performance and comparison